ChristopherJosephMelaniMD

Hematologic Oncology

Staff Clinician, Lymphoid Malignancies Branch, NCI

Dr. Melani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
10 Center Drive
Building 10, Room 4N115
Suburb Maryland Fac, MD 20897

Christopher Melani, MD, is an Oncologist with a subspecialty in Hematologic Oncology based in Suburb Maryland Fac, MD. He completed his residency in Internal Medicine at Johns Hopkins University (2011-2014) and a Fellowship in Hematology and Medical Oncology at the National Institutes of Health Clinical Center (2014-2017). He is a Drexel University College of Medicine alumnus (Class of 2011) and has significant experience in treating lymphoma. Dr. Melani has numerous publications in reputed journals, notably in "Blood Advances" and "The Lancet Haematology," with several of his research articles gathering citations. He was inducted into the Alpha Omega Alpha Honor Medical Society in 2011.

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
Drexel University College of MedicineClass of 2011

PubMed

20 citations
Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma.
Stefania Pittaluga, Alina Nicolae, George E. Wright, Christopher Melani, Mark Roschewski
Blood Cancer Discovery. 2020-09-01
18 citations
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.
Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Nakhle Saba
Blood Advances. 2022-04-26
14 citations
Liquid biopsy in non-Hodgkin's lymphoma.
Christopher Melani, Wyndham H. Wilson, Mark Roschewski
Hematological Oncology. 2019-06-12

Journal Articles

End-of-Treatment and Serial PET Imaging Has Prognostic Value and Clinical Utility in Primary Mediastinal B-cell Lymphoma Following Dose-Adjusted EPOCH-R - Response to ...
Mark Roschewski, Wyndham H Wilson, Christopher Melani, Haematologica

Abstracts/Posters

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...
Christopher Melani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR
Christopher Melani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas
Christopher Melani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Major Survival Gain with Immunotherapy in Lymphomatoid GranulomatosisApril 5th, 2023
New Therapy Cures Cancer with Just One InjectionJanuary 8th, 2019
Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017December 8th, 2017
Join now to see all